MLC1501 Study Assessing Efficacy in Post STrOke Subjects With mOtor Deficits

Summary

This is a multi-center, randomized, double-blind, placebo-controlled trial of MLC1501 in patients with stroke. Eligible participants will be randomized in a 1:1:1 ratio to orally receive MLC1501 high-dose twice a day, MLC1501 low-dose twice a day, or matching placebo for 24 weeks.

Timeline

Start

2023-07-21

Primary completion

2025-07-18

Completion

2025-07-18

Publications

• Chen CPLH, Esagunde RU, Escabillas CG, Hiyadan JH, Advincula JM, Co COC, Collantes MEV, Lao AY, Koh YH, De Silva DA, Tham CH, Lokin JK, Venketasubramanian N. Phase II randomised, double-blind, placebo-controlled trial to assess the efficacy and safety of MLC1501 in patients with stroke: the MLC1501 study Assessing Efficacy in post-STrOke Subjects with mOtor deficits (MAESTOSO) study protocol. Stroke Vasc Neurol. 2025 Oct 27;10(5):657-664. doi: 10.1136/svn-2024-003750.

Drugs

Indications